Biotherapeutic Formulation Factors Affecting Metal Leachables from Stainless Steel Studied by Design of Experiments

被引:30
作者
Zhou, Shuxia [1 ,2 ]
Evans, Brad [3 ]
Schoeneich, Christian [2 ]
Singh, Satish K. [1 ]
机构
[1] Pfizer Inc, Biotherapeut Pharmaceut Sci, St Louis, MO 63017 USA
[2] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA
[3] Biostatistics, St Louis, MO 63017 USA
来源
AAPS PHARMSCITECH | 2012年 / 13卷 / 01期
关键词
biologics formulation factors; metal chelator; metal leachables; protein drug product/drug substance manufacturing; protein formulation stability; MONOCLONAL-ANTIBODY; DIETHYLENETRIAMINEPENTAACETIC ACID; PROTEIN FORMULATIONS; CATALYZED OXIDATION; AGGREGATION; CORROSION; PRECIPITATION; CONSEQUENCES; SERUM; SITE;
D O I
10.1208/s12249-011-9747-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Trace amounts of metals are inevitably present in biotherapeutic products. They can arise from various sources. The impact of common formulation factors such as protein concentration, antioxidant, metal chelator concentration and type, surfactant, pH, and contact time with stainless steel on metal leachables was investigated by a design of experiments approach. Three major metal leachables, iron, chromium, and nickel were monitored by inductively coupled plasma-mass spectrometry. It was observed that among all the tested factors, contact time, metal chelator concentration, and protein concentration were statistically significant factors with higher temperature resulting in higher levels of leached metals. Within a pH range of 5.5-6.5, solution pH played a minor role for chromium leaching at 25A degrees C. No statistically significant difference was observed due to type of chelator, presence of antioxidant, or surfactant. In order to optimize a biotherapeutic formulation to achieve a target drug product shelf life with acceptable quality, each formulation component must be evaluated for its impact.
引用
收藏
页码:284 / 294
页数:11
相关论文
共 30 条
  • [1] Allain L, 2007, AM PHARM REV, V10, P8
  • [2] Allain L, 2007, AM PHARM REV, V10, P42
  • [3] Allain L, 2007, AM PHARM REV, V10, P40
  • [4] [Anonymous], 1999, CONT CLOS SYST PACK
  • [5] Precipitation of a Monoclonal Antibody by Soluble Tungsten
    Bee, Jared S.
    Nelson, Stephanie A.
    Freund, Erwin
    Carpenter, John F.
    Randolph, Theodore W.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (09) : 3290 - 3301
  • [6] ELECTROCHEMICAL CORROSION IN SALINE AND SERUM
    BROWN, SA
    MERRITT, K
    [J]. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1980, 14 (02): : 173 - 175
  • [7] Rational design of stable lyophilized protein formulations: Some practical advice
    Carpenter, JF
    Pikal, MJ
    Chang, BS
    Randolph, TW
    [J]. PHARMACEUTICAL RESEARCH, 1997, 14 (08) : 969 - 975
  • [8] CLELAND JL, 1993, CRIT REV THER DRUG, V10, P307
  • [9] Formulation and delivery issues for monoclonal antibody therapeutics
    Daugherty, Ann L.
    Mrsny, Randall J.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (5-6) : 686 - 706
  • [10] EMEA, 2005, HARM GUID EMEA HLTH